X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (551) 551
humans (481) 481
male (417) 417
index medicus (408) 408
bridged bicyclo compounds, heterocyclic - pharmacokinetics (341) 341
bridged bicyclo compounds, heterocyclic - pharmacology (288) 288
rats (288) 288
pharmacology & pharmacy (267) 267
mice (217) 217
female (212) 212
dose-response relationship, drug (143) 143
bridged bicyclo compounds, heterocyclic - administration & dosage (138) 138
rats, sprague-dawley (132) 132
bridged bicyclo compounds, heterocyclic - chemistry (128) 128
bridged bicyclo compounds, heterocyclic - therapeutic use (128) 128
neurosciences (117) 117
adult (116) 116
bridged bicyclo compounds, heterocyclic (113) 113
chemistry, medicinal (105) 105
pharmacokinetics (102) 102
structure-activity relationship (93) 93
middle aged (92) 92
pyridines - pharmacokinetics (92) 92
receptors, nicotinic - metabolism (92) 92
brain - metabolism (87) 87
oncology (86) 86
cell line, tumor (80) 80
administration, oral (78) 78
biochemistry & molecular biology (67) 67
apoptosis (66) 66
bridged bicyclo compounds, heterocyclic - adverse effects (66) 66
bridged bicyclo compounds, heterocyclic - chemical synthesis (66) 66
in vitro techniques (66) 66
tissue distribution (63) 63
analysis (62) 62
cancer (62) 62
aged (61) 61
bridged bicyclo compounds, heterocyclic - blood (61) 61
bridged bicyclo compounds, heterocyclic - metabolism (59) 59
chemistry, organic (55) 55
nicotinic agonists - pharmacokinetics (55) 55
antineoplastic agents - pharmacology (53) 53
bridged bicyclo compounds - pharmacokinetics (53) 53
ligands (52) 52
pharmacology (52) 52
article (51) 51
brain - drug effects (51) 51
drug interactions (50) 50
rats, wistar (50) 50
time factors (49) 49
radioligand assay (48) 48
brain (47) 47
antineoplastic agents - pharmacokinetics (45) 45
care and treatment (44) 44
binding, competitive - drug effects (43) 43
research (43) 43
bridged bicyclo compounds - pharmacology (42) 42
disease models, animal (42) 42
potent (42) 42
molecular structure (41) 41
dogs (40) 40
half-life (40) 40
sulfonamides - pharmacology (40) 40
chromatography, high pressure liquid (39) 39
medicine & public health (39) 39
pharmacology/toxicology (39) 39
proto-oncogene proteins c-bcl-2 - antagonists & inhibitors (39) 39
autoradiography (38) 38
binding sites (38) 38
biological availability (38) 38
efficacy (38) 38
in-vivo (38) 38
kinetics (38) 38
proteins (38) 38
rat-brain (38) 38
receptor (38) 38
toxicology (38) 38
treatment outcome (38) 38
nicotinic agonists - pharmacology (37) 37
apoptosis - drug effects (36) 36
double-blind method (36) 36
nicotine - pharmacology (36) 36
receptors, nicotinic - drug effects (36) 36
binding (34) 34
cells (34) 34
stereoisomerism (34) 34
cells, cultured (33) 33
drug therapy (33) 33
models, molecular (33) 33
pyridines - pharmacology (33) 33
area under curve (32) 32
cell line (32) 32
chemotherapy (32) 32
mice, inbred c57bl (32) 32
reproducibility of results (32) 32
expression (31) 31
leukemia (31) 31
protein binding (31) 31
radiopharmaceuticals - pharmacokinetics (31) 31
antineoplastic agents - therapeutic use (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (832) 832
Japanese (9) 9
Chinese (5) 5
French (3) 3
German (2) 2
Russian (2) 2
Spanish (2) 2
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
DOSE-ESCALATION | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | CLL | INTERNATIONAL WORKSHOP | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | INHIBITOR | PHASE-I | FLUDARABINE | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2017, Volume 35, Issue 8, pp. 826 - 833
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2018, Volume 36, Issue 19, pp. 1973 - 1980
Journal Article
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 04/2017, Volume 83, Issue 4, pp. 846 - 854
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2013, Volume 8, Issue 4, p. e60933
Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB). Current treatment programs to combat... 
CANDIDATE | SQ109 | IDENTIFICATION | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | Pyrazoles - therapeutic use | Antitubercular Agents - chemistry | Humans | Drug Resistance, Bacterial | Spiro Compounds - therapeutic use | Tuberculosis - microbiology | Chromatography, Thin Layer | Mycobacterium tuberculosis - drug effects | Microbial Sensitivity Tests | Pyrazoles - chemistry | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Tuberculosis - drug therapy | Pyrazoles - pharmacokinetics | Spiro Compounds - chemistry | Antitubercular Agents - therapeutic use | Disease Models, Animal | Pyrazoles - pharmacology | Bacterial Proteins - antagonists & inhibitors | Cord Factors | Microbial Viability - drug effects | Bridged Bicyclo Compounds, Heterocyclic - chemistry | Antitubercular Agents - pharmacology | Rats | Genotype | Treatment Outcome | Mutation - genetics | Mycobacterium tuberculosis - isolation & purification | Spiro Compounds - pharmacokinetics | Hep G2 Cells | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Antitubercular Agents - pharmacokinetics | Dogs | Bacterial Proteins - metabolism | Mice | Kinetics | Spiro Compounds - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Mycobacterium tuberculosis - genetics | Pyrimidines | Tuberculosis | Genomics | Nucleotide sequencing | Drug therapy | Patient compliance | DNA sequencing | Trehalose | Medical treatment | Lung diseases | BCG | Cytotoxicity | Genomes | Drug resistance | Mutants | Gene sequencing | Chemistry | Lungs | Bacteria | Mutation | Piperidine
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2011, Volume 54, Issue 21, pp. 7579 - 7587
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 11/2016, Volume 56, Issue 11, pp. 1335 - 1343
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2016, Volume 22, Issue 12, pp. 2874 - 2884
Journal Article
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2012, Volume 55, Issue 21, pp. 9089 - 9106
Journal Article
Journal Article